Anthem picks Harvoni

Anthem Inc. (NYSE:ANTM) said Thursday it would make Harvoni ledipasvir/ sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) its preferred drug to treat HCV across its employer-based plans.

The payer said

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE